N-DesmethylImatinib , 90% , 404844-02-6
CAS NO.：404844-02-6
Empirical Formula: C28H29N7O
Molecular Weight: 479.58
MDL number: MFCD07369291
EINECS: 1592732-453-0
| Pack Size | Price | Stock | Quantity |
| 25mg | RMB142.40 | In Stock |
|
| 100mg | RMB446.40 | In Stock |
|
| 500mg | RMB1830.40 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 99-101°C |
| Density | 1.268±0.06 g/cm3(Predicted) |
| storage temp. | -20°C Freezer |
| solubility | DMF: 16 mg/ml; DMF:PBS (pH 7.2) (1:4): 0.20 mg/ml; DMSO: 14 mg/ml; Ethanol: 0.20 mg/ml |
| form | A lyophilized solid |
| pka | 13.28±0.70(Predicted) |
| color | Light yellow to yellow |
| biological source | synthetic |
| InChIKey | BQQYXPHRXIZMDM-UHFFFAOYSA-N |
| SMILES | C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)(=O)C1=CC=C(CN2CCNCC2)C=C1 |
Description and Uses
N-desmethyl Imatinib is a major active metabolite of imatinib , an anticancer agent that selectively targets tyrosine kinases, including Bcr-ABL, platelet-derived growth factor receptor (PDGFR), and KIT. N-desmethyl Imatinib is formed when imatinib undergoes demethylation by the cytochrome P450 (CYP) isomer CYP3A4. N-desmethyl Imatinib has the same in vitro potency at Bcr-ABL kinase as imatinib (IC50 = 38 nM for both) but is only present in plasma at 10-15% of the levels of imatinib, indicating the majority of the anticancer activity can be attributed to the parent compound.
anti-epileptic
Safety
| Symbol(GHS) |   GHS07,GHS08 |
| Signal word | Danger |
| Hazard statements | H302-H341-H351-H360-H362 |
| Precautionary statements | P201-P202-P260-P263-P264-P270-P280-P301+P312-P330-P308+P313-P405-P501 |
| Safety Statements | 24/25 |
| HS Code | 29339900 |
